key: cord-1043922-plx7yc8d
authors: Wheatley, Adam K.; Pymm, Phillip; Esterbauer, Robyn; Dietrich, Melanie H.; Lee, Wen Shi; Drew, Damien; Kelly, Hannah G.; Chan, Li-Jin; Mordant, Francesca L.; Black, Katrina A.; Adair, Amy; Tan, Hyon-Xhi; Juno, Jennifer A.; Wragg, Kathleen M.; Amarasena, Thakshila; Lopez, Ester; Selva, Kevin J.; Haycroft, Ebene R.; Cooney, James P.; Venugopal, Hariprasad; Tan, Li Lynn; O’ Neill, Matthew T.; Allison, Cody C.; Cromer, Deborah; Davenport, Miles P.; Bowen, Richard A.; Chung, Amy W.; Pellegrini, Marc; Liddament, Mark T.; Glukhova, Alisa; Subbarao, Kanta; Kent, Stephen J.; Tham, Wai-Hong
title: Landscape of human antibody recognition of the SARS-CoV-2 Receptor Binding Domain
date: 2021-09-25
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109822
sha: f2982c5d50242f40b1064c2259366c0c37b21bc5
doc_id: 1043922
cord_uid: plx7yc8d

Potent neutralising monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOC) that carry multiple mutations in the viral spike protein can exhibit neutralisation resistance, potentially impacting the effectiveness of some antibody-based therapeutics. Here, generation of a diverse panel of 91 human neutralising monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro neutralising potency. Assessing the impact of mutations in the spike protein on antibody recognition and neutralisation highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOC such as B.1.351 and P.1. These neutralizing monoclonal antibodies, and others that bind analogous epitopes, represent potentially useful future anti-SARS-CoV-2 therapeutics.

The global spread of SARS-CoV-2 has sparked intense global research efforts 59 to combat the significant health and economic impacts of the pandemic. Monoclonal 60 antibodies (mAbs) have demonstrated promise as treatments or prophylactic agents 61 against other viral diseases such as RSV (Rocca et al., 2021) and Ebola (Misasi and 62 Sullivan, 2021). The extremely rapid isolation and characterisation of mAbs for the 63 treatment or prevention of COVID-19 has to date yielded hundreds of fully human 64 mAbs with potent antiviral neutralising activity (Brouwer et high potency with an endpoint microneutralisation titre of < 2 μg/ml, comparable with 127 well characterised antibodies casirivimab (REGN10933) and imdevimab 128 (REGN10987) (Hansen et al., 2020) . 129

In parallel, we screened a semi-synthetic human Fab library with a diversity of 130 10 11 , using SARS-CoV-2 spike or RBD. Of the 760 individual phage clones selected, 131 we identified 121 unique clones which we expressed recombinantly (Table S2) 

A subset of 12 potently neutralising RBD-specific mAbs representing diverse 141 germline families (8 from convalescent donors and 4 from phage display) were down-142 selected for further functional and structural analysis. The binding characteristics of 143 each antibody to the RBD was assessed using bio-layer interferometry (BLI), the 144 capacity to block RBD interaction with ACE2 assessed by ELISA, and potent 145 neutralisation activity confirmed using both plaque reduction neutralisation titres 146 (PRNT) and an ELISA-based micro-neutralisation readout (Table S3) . Epitope 147 diversity was assessed by pairwise competition panning using BLI ( Figure 3A ). Based 148 upon clustering patterns of mutual binding inhibition and subsequent structural 149 analysis, we defined six putative epitope clusters distributed widely across the RBD 150 surface ( Figure 3B ); cluster 1 (PDI 37, PDI 42, PDI 222, PDI 231, WCSL 120, WCSL 151 129, REGN10933), cluster 2 (PDI 210), cluster 3 (WCSL 55 and WCSL 119), cluster 152 4 (PDI 215), cluster 5 (PDI 93) and cluster 6 (PDI 96, REGN10987). 153

Structural analysis was carried out by X-ray crystallography using co-complex 154 of Fabs bound to monomeric RBD (9 of 12 mAbs) (Table S4 and S5) and by high-155 resolution cryo-EM using Fab bound to trimeric spike (1 of 12 mAbs) (Table S6) . gene usage, has a longer CDR-H3 at 16 residues (Table S1) that diverges from the 171 public clonotype sequence signatures. The longer CDR-H3 loop is accommodated 172 through an alteration of the conformation of the b-sheet and loop between K45 and 173 G57 which is raised away from the RBD surface. This allows protrusion of the CDR 174 H3 loop across the ACE2 binding surface of the RBD without alteration of the 175 approach angle of the antibody ( Figure 3B ; Figure S2C ). A previously reported VH3-176 53 antibody structure (COVA2-39) with an equivalent length CDR-H3 adopts a 177 different angle of approach to the RBD and the position of the heavy chain is rotated 178 nearly 90 degrees from VH3-53/66 binding mode 1. 179

While not of the same gene usage (Table S2) The capacity of mAbs to mediate antiviral activity in vivo was initially 265 assessed using an isolate of SARS-CoV-2 (D614G N501Y) capable of supporting 266 viral replication in wildtype mice (Pymm et al., 2021) . Mice were given 5, 1 or 0.2 267 mg/kg doses of six different mAbs one day prior to aerosolised challenge with SARS-268

CoV-2, with a primary endpoint of viral titres recoverable within lung homogenates. 269

At 5 mg/kg, significant protection was afforded by all mAbs tested, with protection 270 waning for most mAbs in line with dose ( Figure 5A ). Notably, a good correlation 271 existed between in vitro microneutralisation activity and lung viral titres in mice after 272 treatment with the lowest dose of antibody, suggesting neutralisation potency is a key 273 driver of in vivo protective potential ( Figure 5B ). Based upon the robust protection 274 observed as single agents, two cocktails consisting of pairs of antibodies binding non-275 competing RBD epitopes were selected: WCSL 119/PDI 96 (clusters 3 and 6) and 276 PDI 222/PDI 96 (clusters 1 and 6). When used to prophylactically treat mice, both 277 cocktails demonstrated potent protection at 1 mg/kg, comparable to the benchmark 278 Regeneron cocktail, with some protective effects still observable at the low dose of 279 0.2 mg/kg ( Figure 5C ). 280

We next studied Syrian hamsters, a model with more human-relevant 281 pathogenesis, to further explore the potential of mAbs as treatments and prophylaxis 282 via intraperitoneal injection one day prior to intranasal challenge with SARS-CoV-2 284 as previously described (Schafer et al., 2021) . Passive infusion at 5 mg/kg of each 285 single antibody or a cocktail provided robust protection against SARS-CoV-2-induced 286 weight loss ( Figure 5D ), with levels of virus at 3 dpi virtually undetectable in the 287 cranial ( Figure 5E ) or the caudal lung ( Figure S6 ). Virus levels within nasal turbinates 288 (3 dpi) or recovered from swabs (1-3 dpi) were dramatically reduced relative to 289 animals dosed with isotype controls, suggesting accelerated viral clearance after 290 challenge ( Figure S6 ). Reduced protection was observed at 0.25 mg/kg dosing, 291 however an ~1.5 log reduction in viral levels in the lung and nasal passage and 292 reduced weight loss were still evident. The contribution of Fc-mediated effector 293 functions was assessed using variants of PDI 96 and PDI 222 modified with inclusion 294 of LALA mutations proven to abrogate Fc-receptor engagement across a wide range 295 of species (Saunders, 2019) . Both weight loss and viral levels in the lung were 296 unchanged relative to unmodified antibodies ( Figure S6 ), suggesting protection is 297 primarily driven by neutralisation potency alone in this model. We similarly 298 compared the protective capacity of a cocktail of three non-competing RBD mAbs 299 (PDI 96, PDI 222 and PDI 215), however no additional protective benefit from 300 inclusion of a third mAb was observed ( Figure S6 ). 301

Gross pathology in the lung was assessed using haemotoxylin and eosin 302 staining on animals sacrificed at 3 and 7 dpi. We found infusion with 5 mg/kg PDI 96 303 or the PDI 96/222 cocktail provided robust protection against lung pathology 304 associated with SARS-CoV-2 challenge ( Figure 5F directly contact at least one residue mutated in the VOC but suffer only a partial 333 reduction (3-4-fold relative to WT) of neutralisation potency ( Figure 6C ). Hydrogen 334 bonds between WCSL 119 and RBD residue E484 are solely with the peptide 335 backbone ( Figure 7E ), which may be less impacted by substitution, while WCSL 129 336 forms hydrogen bonds with K417 ( Figure 7F ), though some of these might also be 337 maintained with a K417N substitution. PDI 93 forms a hydrogen bond with residue 338 E484 and PDI 210 forms Van der Waals contacts with RBD residues E484 and N501 339 (Table S7) . 

Significant global research effort has yielded many promising antibodies and 359 antibody-based biologics for prophylaxis or treatment of COVID-19. The utility of 360 combining two or more antibodies into cocktails to limit the selection of viral escape 361 mutants has been established in vitro (Baum et al., 2020b; Weisblum et al., 2020) . 

Extremely potent human 1054 monoclonal antibodies from COVID-19 convalescent patients

CD40/anti-CD40 1058 antibody complexes which illustrate agonist and antagonist structural switches

CoV-2 neutralizing antibody structures inform therapeutic strategies

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common 1067 Epitopes and Recurrent Features of Antibodies

REGN-COV2 antibodies prevent and 1070 treat SARS-CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 1074 spike protein prevents rapid mutational escape seen with individual antibodies

Potent neutralizing antibodies from COVID-19 patients define multiple targets of 1079 vulnerability

Potent SARS-CoV-2 neutralizing antibodies 1082 directed against spike N-terminal domain target a single supersite

Convergent 1086 antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated 1087 individuals

Resistance of SARS-CoV-2 1090 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Structure of the 4-1BB/4-1BBL 1094 complex and distinct binding and functional properties of utomilumab and urelumab

The antigenic anatomy of 1098 SARS-CoV-2 receptor binding domain

Genetic and structural basis for 1101 recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy 1104 in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Features and 1107 development of Coot

Neutralization potency of 1110 monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-1111

CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity

Structural basis for 1114 Zika envelope domain III recognition by a germline version of a recurrent neutralizing 1115 antibody

Antibodies elicited by mRNA-1273 1118 vaccination bind more broadly to the receptor binding domain than do those from 1119 SARS-CoV-2 infection

Mutational escape from 1122 the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a 1123 single class of antibodies

Complete Mapping 1126 of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape 1127 Antibody Recognition

Studies in humanized mice and 1130 convalescent humans yield a SARS-CoV-2 antibody cocktail

Structure-based design of 1134 prefusion-stabilized SARS-CoV-2 spikes

HIV-1 1137 broadly neutralizing antibody precursor B cells revealed by germline-targeting 1138 immunogen

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in 1142 nonhuman primates

SARS-CoV-2 spike in individuals recovered from COVID-19. medRxiv

Humoral and circulating 1149 follicular helper T cell responses in recovered patients with COVID-19

XDS

Neutralization of West 1154 Nile virus by cross-linking of its surface proteins with Fab fragments of the human 1155 monoclonal antibody CR4354

Neutralising antibodies in 1158 Spike mediated SARS-CoV-2 adaptation

Inference of macromolecular assemblies from 1160 crystalline state

Macromolecular 1163 structure determination using X-rays, neutrons and electrons: recent developments in 1164 Phenix

Reduced 1167 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 1168 online ahead of print

Potent neutralizing antibodies against multiple epitopes 1171 on SARS-CoV-2 spike

Inhibiting complex IL-17A and 1174 IL-17RA interactions with a linear peptide

N-terminal domain 1177 antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Potent antibody lineage 1180 against malaria transmission elicited by human vaccination with Pfs25

Immunotherapeutic strategies to target 1183 vulnerabilities in the Ebolavirus glycoprotein

Human B Cell 1186 Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2

CSL311, a novel, 1190 potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the 1191 common beta chain of the IL-3, GM-CSF and IL-5 receptors

UCSF Chimera--a visualization system for exploratory 1194 research and analysis

UCSF ChimeraX: Structure visualization for 1197 researchers, educators, and developers

Mapping 1200 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-1201 Binding Domain by Structure-Guided High-Resolution Serology

cryoSPARC: 1204 algorithms for rapid unsupervised cryo-EM structure determination

Nanobody cocktails 1208 potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

Modular basis for potent SARS-CoV-2 1212 neutralization by a prevalent VH1-2-derived antibody class

Convergent 1215 antibody responses to SARS-CoV-2 in convalescent individuals

Passive Immunoprophylaxis against Respiratory Syncytial Virus in 1219 Children: Where Are We Now?

Isolation of potent SARS-CoV-2 1222 neutralizing antibodies and protection from disease in a small animal model

Conceptual Approaches to Modulating Antibody Effector 1225 Functions and Circulation Half-Life

Antibody 1228 potency, effector function, and combinations in protection and therapy for SARS-1229

CoV-2 infection in vivo

Prior infection and passive transfer of 1232 neutralizing antibody prevent replication of severe acute respiratory syndrome 1233 coronavirus in the respiratory tract of mice

Sequence signatures of 1236 two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain

Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev 1240 Immunol

Efficient generation of monoclonal antibodies from single human B cells 1243 by single cell RT-PCR and expression vector cloning

Ultrapotent human 1247 antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Prevalent, protective, 1251 and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

A 1255 conserved immunogenic and vulnerable site on the coronavirus spike protein 1256 delineated by cross-reactive monoclonal antibodies

Increased resistance of SARS-CoV-2 1259 variant P.1 to antibody neutralization

Antibody resistance of SARS-CoV

1265 mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Escape 1269 from neutralizing antibodies by SARS-CoV-2 spike protein variants

Anti-idiotypic antibody K1-18 engages VH1-69 precursor and affinity-1275 matured, anti-stem antibodies through mimicry of the HA stem

Human neutralizing antibodies against 1279 SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Overview of 1283 the CCP4 suite and current developments

An alternative binding mode of 1287 IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

Germline IGHV3-53-encoded RBD-targeting neutralizing

A highly conserved cryptic epitope in the receptor binding domains of 1294 SARS-CoV-2 and SARS-CoV

Structural basis of a shared antibody response to SARS-1297

Structural and functional ramifications of 1300 antigenic drift in recent SARS-CoV-2 variants. Science, onloine ahead of print

Gctf: Real-time CTF determination and correction

MotionCor2: anisotropic correction of beam-induced motion for improved 1306 cryo-electron microscopy

Evidence of escape 1309 of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

New tools for automated high-resolution cryo-EM structure 1312 determination in RELION-3

Potently neutralizing and 1315 protective human antibodies against SARS-CoV-2

Rapid isolation and 1318 profiling of a diverse panel of human monoclonal antibodies targeting the SARS-1319

CoV-2 spike protein

Complementary recognition of the receptor-binding site of 1322 highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies. J Landscape of human antibody recognition of the SARS-CoV-2 Receptor Binding Domain CELL

Highlights Neutralising monoclonal antibodies block SARS-CoV-2 virus entry. Reduced SARS-CoV-2 infection in mice and hamsters. Leading antibodies unaffected by VOC such as B1.1.7., B.1.351 and P.1. Cryo-EM and crystallography reveal the epitope landscape of neutralising antibodies

Dimethyldodecylamine N-oxide (LDAO), 0.2 M sodium sulphate seeded from initial 897 screens. Mother liquor containing 6 % glycerol was used as cryo-protectant for 898 SARS-CoV-2 RBD-WCSL 129-PDI 93 and mother liquor containing 20 % 899 butanediol was used for SARS-CoV-2 RBD-PDI 231 crystals. 900 901 X-ray diffraction data was collected at the MX2 beamline at the Australian 902 Synchrotron, recorded with an Eiger 16M detector (Dectris) and processed using the 903 XDS package (Kabsch, 2010 Figure S2 : Antibod AC 2 footprint o erlaps Antibod Centre of ass and Antibod contacting C R loops Related to Figure . A ACE2 footprint overlapAxes showing antibody centre of mass and binding angle C Placements of antibody CDR loops contacting the SARS-CoV-2 RBD surface.